Enliven Therapeutics (NASDAQ:ELVN) Insider Joseph Lyssikatos Sells 41,302 Shares

Enliven Therapeutics, Inc. (NASDAQ:ELVN) insider Joseph Lyssikatos sold 41,302 shares of the stock in a transaction dated Thursday, January 8th. The stock was sold at an average price of $24.05, for a total value of $993,313.10. Following the sale, the insider owned 856,386 shares of the company’s stock, valued at $20,596,083.30. This represents a 4.60% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Enliven Therapeutics Stock Down 3.7%

NASDAQ ELVN traded down $0.97 during trading hours on Monday, reaching $25.03. The company’s stock had a trading volume of 1,373,161 shares, compared to its average volume of 2,697,186. Enliven Therapeutics, Inc. has a 1 year low of $13.30 and a 1 year high of $29.98. The company has a market capitalization of $1.49 billion, a price-to-earnings ratio of -13.60 and a beta of 0.41. The firm’s 50-day moving average price is $19.07 and its 200-day moving average price is $19.95.

Enliven Therapeutics (NASDAQ:ELVN) last announced its quarterly earnings data on Thursday, November 13th. The company reported ($0.32) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.43) by $0.11. Equities research analysts anticipate that Enliven Therapeutics, Inc. will post -1.95 EPS for the current fiscal year.

Analysts Set New Price Targets

ELVN has been the topic of several research analyst reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Enliven Therapeutics in a research note on Wednesday, October 8th. Wall Street Zen upgraded Enliven Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, November 15th. Four analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $41.00.

Hedge Funds Weigh In On Enliven Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Vestal Point Capital LP increased its holdings in shares of Enliven Therapeutics by 364.0% in the 3rd quarter. Vestal Point Capital LP now owns 1,160,000 shares of the company’s stock worth $23,745,000 after buying an additional 910,000 shares during the last quarter. TCG Crossover Management LLC purchased a new position in Enliven Therapeutics in the second quarter worth about $9,990,000. Duquesne Family Office LLC increased its stake in Enliven Therapeutics by 104.6% during the third quarter. Duquesne Family Office LLC now owns 947,405 shares of the company’s stock worth $19,393,000 after acquiring an additional 484,405 shares during the last quarter. Candriam S.C.A. purchased a new stake in Enliven Therapeutics during the second quarter valued at approximately $8,358,000. Finally, Franklin Resources Inc. raised its position in Enliven Therapeutics by 2,029.3% during the second quarter. Franklin Resources Inc. now owns 430,240 shares of the company’s stock valued at $8,631,000 after purchasing an additional 410,034 shares during the period. 95.08% of the stock is owned by hedge funds and other institutional investors.

About Enliven Therapeutics

Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.

The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.